remibrutinib

Modality

small molecule (kinase inhibitor)

Mechanism

12.1 Mechanism of Action Remibrutinib is an oral, small molecule kinase inhibitor that inhibits Bruton’s tyrosine kinase (BTK). BTK is an intracellular protein expressed in mast cells, basophils, B cells, macrophages, and thrombocytes. BTK is involved in intracellular signaling via Fc epsilon receptor-1 (FcεR1), Fc gamma receptors (FcγR), and the B cell antigen receptor (BCR). Remibrutinib also inhibits the BTK-related kinases tec protein tyrosine kinase (TEC) and BMX non-receptor tyrosine kinase (BMX). Remibrutinib inhibits mast cell and basophil degranulation, including release of histamine and other proinflammatory mediators, mediated by pathogenic IgE or IgG directed against the FcεR1 or IgE.

Targets

—

Storage

—

Approved

chronic urticaria — FDA

In trial

chronic urticaria

Sources

DailyMed (FDA label)ClinicalTrials.gov

Last verified

2026-04-23

No curated MOA diagram yet. See lib/moa-data.ts for the shape; add an entry keyed by remibrutinib.